Tada, Yayoi
Soliman, Ahmed M.
Ishii, Kanako
Sakuma, Ryuta
Puig, Luis
Davis, Matthew
Nunag, Dominic
Pinter, Andreas
Imafuku, Shinichi
Funding for this research was provided by:
AbbVie
Article History
Received: 18 August 2023
Accepted: 25 October 2023
First Online: 29 November 2023
Declarations
:
: Yayoi Tada: Reports grants, personal fees, and nonfinancial support from Kyowa Kirin, Eli Lilly Japan, AbbVie, Maruho, Celgene, Taiho Pharmaceutical, Mitsubishi Tanabe Pharma, Novartis Pharma, Sanofi, UCB Japan, Torii Pharmaceutical, LEO Pharma, Eisai, Kaken Pharmaceutical, Pfizer, Ushio, Meiji Seika Pharma, Nippon Boehringer Ingelheim, JIMRO, Bristol Myers Squibb, Sun Pharma, and TOKIWA Pharmaceutical outside the submitted work; grants and nonfinancial support from Kanebo Cosmetics, MSD, Ono Pharmaceutical, Pola Pharma, Nihon Pharmaceutical, Smith & Nephew, and Sato Pharmaceutical outside the submitted work; personal fees and nonfinancial support from Janssen Pharmaceuticals outside the submitted work; grants from Japan Blood Products Organization, Mochida Healthcare, Oshimatsubaki, and Shionogi outside the submitted work; and personal fees from Chugai Pharmaceutical outside the submitted work. Ahmed M. Soliman, Kanako Ishii, and Ryuta Sakuma: Employees of AbbVie and may own AbbVie stock. Luis Puig: Has received honoraria for serving on advisory boards and speakers’ bureaus or for consulting, and institutional grants for investigator activities sponsored by AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Leo-Pharma, Lilly, Novartis, Pfizer, Sandoz, Sanofi, and UCB. Matthew Davis and Dominic Nunag: Employees of Medicus Economics, LLC, which received funding from AbbVie to participate in this research. Andreas Pinter: Received honoraria as an investigator and/or received speakers' honoraria and/or received grants and/or has been an advisor for the following companies: AbbVie, Almirall, Amgen, Biogen Idec, Boehringer Ingelheim, Celgene, Celltrion, GSK, Eli Lilly, Galderma, Hexal, Janssen, LEO Pharma, MC2, Medac, Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Roche, Sandoz Biopharmaceuticals, Sanofi-Genzyme, Schering-Plough und UCB Pharma. Shinichi Imafuku: Reports grants and personal fees from AbbVie, Eisai, Kaken Pharmaceutical, Kyowa Kirin, Sato Pharmaceutical, Sanofi, Taiho Pharmaceutical, Mitsubishi Tanabe Pharma, Tsumura, Torii Pharmaceutical, Nippon Zoki Pharmaceutical, Novartis Pharma, Maruho, and LEO Pharma outside the submitted work; grants from Pola Pharma outside the submitted work; and personal fees from Astellas, Eli Lilly Japan, MSD, Otsuka Pharmaceutical, Ono Pharmaceutical, Sun Pharma, GSK, JIMRO, Celgene, Daiichi Sankyo, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, Japan Blood Products Organization, Pfizer, Bristol Myers Squibb, Meiji Seika Pharma, Janssen Pharmaceutical, and UCB Japan outside the submitted work.
: This article does not contain any studies with human participants or animals performed by any of the authors. Database permission was obtained via a license from the provider; however, the database is otherwise not publicly available. Because deidentification was conducted before providing claims to researchers, and no identifiable protected health information was included in the data used, Institutional Review Board approval was not required. All analyses were conducted in compliance with RECORD-PE guidance and in accordance with the ethical standards in the 1964 Declaration of Helsinki and its subsequent amendments [CitationRef removed].